CureVac NV
(XTER:5CV)
€
2.912
-0.018 (-0.61%)
Market Cap: 667.92 Mil
Enterprise Value: 500.70 Mil
PE Ratio: 0
PB Ratio: 1.83
GF Score: 47/100 - Q4 2023 CureVac NV Earnings Call TranscriptApr 24, 2024€2.27 (-4.70%)Earnings
- Q3 2023 CureVac NV Earnings Call TranscriptNov 14, 2023€5.35 (+6.79%)Earnings
- CureVac NV at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- Q4 2022 CureVac NV Earnings Call TranscriptApr 25, 2023€6.95 (-5.18%)Earnings
- CureVac NV Annual Shareholders Meeting TranscriptMar 28, 2023
- CureVac NV Preliminary Phase 1 Data from Joint COVID-19 and Flu mRNA Vaccine Development Programs TranscriptJan 06, 2023
- Q3 2022 CureVac NV Earnings Call TranscriptNov 16, 2022€7.89 (+2.04%)Earnings
- CureVac NV Annual Shareholders Meeting TranscriptJun 22, 2022
- CureVac NV at JMP Securities Life Sciences Conference TranscriptJun 15, 2022
- CureVac NV at Jefferies Healthcare Conference TranscriptJun 09, 2022
- CureVac NV at Bank of America Healthcare Conference TranscriptMay 10, 2022
- Q4 2021 CureVac NV Earnings Call TranscriptApr 28, 2022€15.2 (-1.05%)Earnings
- Q3 2021 CureVac NV Earnings Call TranscriptNov 19, 2021€36.83 (+4.54%)Earnings
- CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call TranscriptOct 12, 2021
- CureVac NV Final Analysis of Phase 2b/3 Clinical Trial Of CVnCoV - Investor Call TranscriptJul 01, 2021
- CureVac NV Updates On Clinical Trial - Corporate Call TranscriptJun 17, 2021
- Q4 2020 CureVac NV Earnings Call TranscriptApr 15, 2021€89 (+3.91%)Earnings
- CureVac N.V. - Special Call TranscriptFeb 05, 2021
CureVac NV at JMP Securities Life Sciences Conference Transcript
Jun 15, 2022 / 01:30PM GMT
Release Date Price:
€13.12
(+1.36%)
Douglas Royal Buchanan
JMP Securities LLC, Research Division - Director & Equity Research Analyst
Thank you. Thanks, everyone, for joining us for the JMP Securities Life Sciences Conference. My name is Roy Buchanan, a biotech analyst. We have with us today, Pierre Kemula, Chief Financial Officer of CureVac, tell us a bit about CureVac.
Questions & Answers
Douglas Royal Buchanan
JMP Securities LLC, Research Division - Director & Equity Research Analyst
So I'm actually going to start since we have the CFO up here, start on cash. I think we had about 2 years of cash in our model. Can you just describe where you are in cash, how far it gets you? There's a little bit more cost for this CVnCoV wind-down than we expected in 1Q. What's the outlook for that going forward? Is there more remaining?
Pierre Kemula
CureVac N.V. - MD, CFO & Member of Management Board
Great. Well, thank you, Roy. Good morning to everyone. It's a pleasure to be here. So happy to take the question, of course. So we ended Q1
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)